Crunchbase News recently spoke with Kyle Pretsch, a general partner at Bambu Ventures, about the firm's unique gambit of agreeing to buy telemedicine platform Lemonaid Health from now-bankrupt 23andMe ...

Anne Wojcicki is poised to regain control of genetics testing company 23andMe, which she cofounded and led until earlier this year, after agreeing to put much of her personal fortune on the line. Why ...

(WKBN) – A federal judge has given the green light for the sale of genetics and biotech company 23andMe. 23andMe Holding Co. will be sold to TTAM Research Institute, a genetics-led healthcare company ...

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ:REGN) PD-1 inhibitor Libtayo (cemiplimab-rwlc) as an adjuvant treatment for adult patients ...

Oct 8 (Reuters) - The U.S. Food and Drug Administration on Wednesday cleared Regeneron Pharmaceuticals’ (REGN.O), opens new tab immunotherapy, Libtayo, as an add-on treatment for skin cancer patients ...

On her mother’s instruction, a toddler gives her pink stuffed horse, Snap Snap, a big cuddle. Then, as told, she plants a kiss on his soft fur and, because he’s hungry, feeds him a pretend bowl of ...

Regeneron Pharmaceuticals expects to record an acquired in-process research-and-development charge of approximately $83 million in the third quarter. The pre-tax charge stems from an $80 million ...

It appears problems at Novo Nordisk’s recently acquired manufacturing facility in Indiana aren’t going to be solved any time soon. The FDA has tagged the former Catalent facility with an official ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A federal judge in St. Louis has ...

Genetic deficiency of otoferlin, a protein critical to synaptic transmission by the sensory hair cells of the ear, causes congenital deafness. Medicines to treat the condition are lacking; children ...

Halozyme Therapeutics has been busy. While fighting a patent dispute with Merck & Co. and navigating the impact of the Inflation Reduction Act (IRA), the company has penned an acquisition of fellow ...

Moderna has shared some of the phase 1/2 data that persuaded it to expand and prioritize development of a cancer candidate, reporting responses in melanoma patients failed by checkpoint inhibitors.